References
- Jorm A F, Korten A E, Henderson A S. The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatica Scandinavica 1987; 76: 465–479
- Allen H, Burns A. Non-cognitive features of dementia. Reviews in Clinical Gerontology 1995; 5: 59–75
- Gray A, Fenn P. Alzheimer's disease, the burden of illness in England. Health Trends 1993; 25: 31–37
- Bosanquet N. Editorial: the socioeconomic impact of alzheimer's disease. International Journal of Geriatric Psychiatry 2001; 16: 249–253
- Folstein M F, Folstein S E, McHugh P R. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatry Research 1975; 12: 189–198
- Rosen W G, Mohs R C, Davis K L. A new rating scale for alzheimer's disease. American Journal of Psychiatry 1984; 141: 1356–1364
- Commonwealth Department of Health and Aged Care. Schedule of pharmaceutical benefits for approved pharmacists and medical practioners. Commonwealth of Australia. August, 2001
- McKeith I G, Glasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113–1124
- Shergill S, Mullan E, D'Ath P, Katona C. What is the clinical prevalence of Lewy body dementia?. International Journal of Geriatric Psychiatry 1994; 9: 907–912
- McKeith I G, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. British Medical Journal 1992; 303: 673–678
- Schneider L S, Pollock V E, Lyness S A. A meta-analysis of controlled trials of neurolepts in dementia. Journal of American Geriatric Society 1990; 38: 553–563
- Street J S, Clark W S, Gannon K S, et al. Olanzapine treatment of psychotic and behavioural symptoms in patients with Alzheimer's Disease in nursing care facilities. Archives of General Psychiatry 2000; 57: 968–976
- Cummings J L, Donohue J A, Brooks R L. The relationship between Donepezil and behavioural disturbances in patients with Alzheimer's disease. American Journal of Geriatric Psychiatry 2000; 8: 134–140
- Mega M S, Masterman D M, O'Connor S M, Barclay T R, Cummings J L. The spectrum of behavioural responses to cholinesterase inhibitor therapy in alzheimer's disease. Archives of Neurology 1999; 56: 1388–1393
- Lanctot K, Herrman N. Donepezil for behavioural disorders associated with lewy bodies: a case series. International Journal of Geriatric Psychiatry 2000; 15: 338–345
- Daly E J, Falk W E, Brown P. Cholinesterase inhibitors for behavioural disturbance in dementia. Current Psychiatry Reports 2001; 3: 251–258
- Mckeith I G, Del Ser T, Spano P F, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000; 356: 2031–2036
- World Health Organization. ICD-10 classification of mental and behavioural disorders. World Health Organization, Geneva 1992